Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia

Journal of the Pakistan Medical Association

Volumn 52, Issue 1, 2002, Pages 15-18

  Malik, I ^a   Shaharyar, ^a  

^a National Cancer Institute   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CEFTAZIDIME; MEROPENEM;

ADULT; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DRUG INDICATION; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; MALE; NEUTROPHIL; OUTCOMES RESEARCH;

ADULT; ANTINEOPLASTIC AGENTS; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; FEVER; HUMANS; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; THIENAMYCINS;

EID: 0036220880     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N. Engl. J. Med., 1993;398:1323-31.
2. Freifeld AG, Walsh TJ, Pizzo PA. Infections inthe cancer patient. In: Cancer principle and practice of oncology. 5th ed. Philadephia: Lippincott-Raven, 1997.pp.2659-704.
3. Pizzo PA, Hathron JW, Hiemenz J, et al. A randomized trial comparing ceftazidime antibiotic therapy in cancer patients with fever neutropenia. N. Engl. J. Med., 1986;315:552-5.
4. Ralston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med., 1992;152:283-91.
5. Layland MJ, Bayston KF, Cohen J, et al. A comparative study of imepenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with hematological malignancies. J. Antimicrob. Chemother., 1992;30:843-54.
6. De Pauw BE, Deresinski SC, Feld R. et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann. Intern. Med., 1994;120:834-44.
7. Freifeld A, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imepenem. J. Clin. Oncol., 1995;13:165-76.
8. Malik IA, Abbas Z, Karim M. Randomized comparison of oral ofloxacin alone with combination of parental antibiotics in neutropenic febrile patients. Lancet. 1992;339:1092-6.
9. The Meropenem Study Group of Leuvan, London and Nijnegan. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J. Antimicrob. Chemother., 1995;36:185-200.
10. Cometta A, Calandra T, Gaya H, et al. International Antimicrobial Therapy Cooperative Group: monotherapy with merepenem versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in granulocyttopenic patients with cancer. Antimicrob. Agents. Chemother., 1996;40:1108-15.
11. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-centre validation of a prediction rule. J. Clin. Oncol., 1992;10:316-22.
12. Klastersky J, Paesmans M, Rubenstein E. et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J. Clin. Oncol., 2000;18:3038-51.
13. Lucas KG, Brown AE, Armstrong D. et al. The identification of febrile neutropenic children with neoplastic diseas at low risk for bacteremia and complications of sepsis. Cnacer. 1996;77:791-8.
14. Petrilli AS, Melarango R, Barros KVT, et al. Fever and neutropenia in children with cancer: a therapeutic appraoch related to the underlying disease. Pediatr. Infect. Dis., 1993;12:916-21.
15. Leong DC, Kinlay S, Ackland S. et al. Low-risk febrile neutropenia in a medical oncology unit. Aust. NZ. Med., 1997;27:403-7.
16. Feld R, Depaum B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J. Clin. Oncol., 2000;18:3690-8.